Baidu
map

消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗

2023-09-30 国外肿瘤科相关专家小组（统称） Front Oncol 发表于上海

胆管癌

目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。

中文标题：

2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗

英文标题：

Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2023-09-30

简要介绍：

局部晚期或转移性胆管癌是一种预后差的侵袭性癌症。对于局部晚期或转移性胆管癌的一线治疗，顺铂/吉西他滨已作为标准治疗方案超过10年。目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=fafd51c0033a11bc, title=2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗, enTitle=Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement, guiderFrom= Front Oncol, authorId=0, author=, summary=目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。, cover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Sat Sep 30 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<div class="guideDetailsCont flex-row-between-start" style="color: #333333;"> <div class="detailsContRight" style="color: #222222;"> <p>局部晚期或转移性胆管癌是一种预后差的侵袭性癌症。对于局部晚期或转移性胆管癌的一线治疗，顺铂/吉西他滨已作为标准治疗方案超过10年。目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。</p> </div> </div> <div class="detailsQRWrapper" style="color: #333333;"> <div id="app_detail" class="detailsQR" title="https://m.medlive.cn/guide/1/29820">&nbsp;</div> </div>, tagList=[TagDto(tagId=2872, tagName=胆管癌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=2872, articleKeyword=胆管癌, articleKeywordNum=6, guiderKeywordId=2872, guiderKeyword=胆管癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4989, appHits=18, showAppHits=0, pcHits=355, showPcHits=4968, likes=1, shares=4, comments=4, approvalStatus=1, publishedTime=Mon Sep 18 14:50:00 CST 2023, publishedTimeString=2023-09-30, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=6, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Sep 18 12:12:40 CST 2023, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Fri Jan 05 01:03:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗.pdf)])
2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-12-04 在风中 来自甘肃省

    值得学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-10-31 yixueyuan 来自江苏省

    认真学习，收获满满

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-10-31 1dea4a7em68(暂无匿称) 来自福建省

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-09-18 54414749 来自湖北省

    认真学习!

    0

相关指南

2022 AASLD实践指南：原发性硬化性胆管炎和胆管癌

美国肝病研究学会(AASLD,American Association for the Study of Liver Diseases) · 2023-02-02

胆管癌光动力治疗临床应用技术规范专家共识

中国医师协会外科医师分会胆道外科医师委员会 · 2023-03-27

胆管癌患者光动力治疗避光管理的最佳证据总结

广州医科大学附属第二医院肝胆外科一区 · 2022-12-10

2022 ESMO临床实践指南：胆管癌的诊断，治疗以及随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2022-11-03

2020 意大利临床实践指南：胆管癌-第1部分：分类，诊断和分期

意大利肝病学会(AISF,Italian Association for the Study of the Liver) · 2020-09-03

2016 ESMO临床诊疗指南：胆管癌的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-09-20

拓展阅读

Gut：PRMT5作为胆管癌的潜在治疗靶点！

胆管癌（CCA）是一种极具侵袭性的恶性肿瘤，根据其在胆道系统中的位置，可分为肝内（iCCA）、肝门周围和远端CCA，其中后两者统称为肝外CCA（eCCA）。全球CCA的发病率呈现上升趋势，主要是由于肝

奇效！靶向药艾伏尼布治疗携带IDH1基因R132突变胆管癌！

胆管癌发病率上升，标准治疗效果不佳。介绍艾伏尼布对携带 IDH1 突变胆管癌患者的疗效，通过两病例展示其持久缓解。

赵海涛教授组稿｜张楠：胆道系统肿瘤免疫治疗进展

本期「专家组稿」由北京协和医院赵海涛教授担任执行主编，与北京协和医院张楠博士共同分享《胆道系统肿瘤免疫治疗进展》，为医者和患者提供更多参考。

Lancet Gastroenterol：度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆管癌：TOPAZ-1 研究更新后的总生存期和安全数据

该研究旨在评估度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆管癌的疗效和安全性，度伐利尤单抗联合吉西他滨和顺铂可以显著改善晚期胆管癌患者的总生存期、无进展生存期、客观缓解率和缓解持续时间，并且安全性良好。

CLIN CANCER RES | Nanvuranlat 显著改善晚期胆管癌患者 PFS：一项随机对照研究

该研究旨在评估Nanvuranlat单药治疗在晚期胆管癌二线及后续治疗中的疗效和安全性，与安慰剂相比，Nanvuranlat能够显著改善晚期和难治性胆管癌患者的 PFS，并且具有良好的安全性。

Adv Sci：华中科技大学顾劲扬团队开发一种仿生化集成纳米治疗平台，为胆管癌治疗提供了一种安全高效的全新治疗策略

该研究开发了一种仿生化集成纳米治疗平台—R-CM@MSN@BC，为胆管癌治疗提供了一种安全高效的全新治疗策略。

2015 胆管癌诊断与治疗——外科专家共识

中华医学会外科学分会 · 2015-01-15

肝门部胆管癌规范化诊治专家共识（2015）

中国抗癌协会(Chinese Anti-cancer Association) · 2015-08-30

肝门部胆管癌诊断和治疗指南（2013版）的解读与思考

暂未更新 · 2016-06-08

AHPBA专家共识声明：肝内胆管癌（2015年）

美国肝胰胆协会(AHPBA,American Hepato-Pancreato-Biliary Association) · 2016-06-08

2016 ESMO临床诊疗指南：胆管癌的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-09-20

2020 意大利临床实践指南：胆管癌-第1部分：分类，诊断和分期

意大利肝病学会(AISF,Italian Association for the Study of the Liver) · 2020-09-03

Baidu
map
Baidu
map
Baidu
map